Strategic Partnership for Clinical Trials
Bionical Emas has entered a significant, exclusive global clinical trial supply agreement with Pharma Resources GmbH, a noted German pharmaceutical firm specializing in oncology. This partnership positions Bionical Emas to distribute a vital range of EU-marketed oncology injectables, notably Fluorouracil, which has recently encountered critical shortages across the continent.
Addressing Significant Oncology Drug Shortages
The urgency for this collaboration comes amid substantial disruptions caused by ongoing 5-Fluorouracil shortages, significantly impacting cancer treatments and clinical trials internationally. Bionical Emas, leveraging its extensive global network and agile supply model, seeks to reduce delivery times drastically—from several months to mere weeks—allowing for quicker access to necessary medications.
Commitment to Improving Patient Outcomes
Tom White, Senior Vice-President of Strategic Alliances at Bionical Emas, emphasized, "This strategic agreement underscores our unwavering commitment to delivering innovative, patient-focused solutions to the clinical trial community. Pharma Resources’ dedication and flexibility make them an exceptional partner in our goal to ensure uninterrupted access to crucial oncology drugs for patients globally." This statement reflects the shared vision of streamlining access to essential oncological treatments.
Enhancing Clinical Trial Supply Capabilities
Juliana Dodillet, Managing Director of Pharma Resources, expressed her excitement about the partnership, stating, "We are thrilled to work with Bionical Emas. Their global reach and expertise in clinical trial supply make them the ideal partner for launching our inaugural clinical trial supply program. This partnership is crucial, especially considering the current Fluorouracil shortages that affect patient access across Europe." This collaboration aims to facilitate the development of new therapies and improve patient outcomes during challenging times.
Global Networks and Innovative Solutions
This partnership not only strengthens Bionical Emas' role as a trusted global supply partner but also enhances its position in the clinical trials sector by providing a fast and reliable supply chain. With a keen focus on advanced demand forecasting and strategic inventory management, the alliance between Bionical Emas and Pharma Resources aims to tackle the complexities of the supply chain, accelerating the timelines of clinical trials.
About Bionical Emas
Bionical Emas is committed to bringing life-changing medicines to those in need worldwide. By providing comprehensive Clinical Trial Supply (CTS) and Early Access Programs (EAP), the group supports several leading pharmaceutical and biotechnology companies. Their approach is designed to meet the evolving demands of the global healthcare landscape.
About Pharma Resources
Pharma Resources GmbH operates in the pharmaceutical realm, focusing specifically on generic oncology products. The firm offers a full-service solution, managing everything from regulatory approvals to distribution, ensuring a high-quality and reliable supply chain which is vital for the advancement of oncological therapies.
Frequently Asked Questions
What is the purpose of the partnership between Bionical Emas and Pharma Resources?
The partnership aims to enhance the supply of essential oncology injectables for clinical trials, addressing critical shortages that can disrupt cancer treatments.
How will this partnership affect the delivery times of oncology drugs?
By leveraging Bionical Emas' global network and supply model, delivery times will be significantly reduced from months to weeks, ensuring faster access to medications.
What specific oncology injectable is highlighted in this agreement?
Fluorouracil is specifically noted as a critical oncology injectable experiencing shortages in the market.
What are the expected benefits for patients from this partnership?
This partnership is expected to improve patient outcomes by ensuring uninterrupted access to essential oncology treatments, particularly during times of drug shortages.
How can clinical trial inquiries be made?
For any clinical trial inquiries, interested parties are encouraged to contact Bionical Emas directly through their channels for further assistance.
